American Journal of Cardiology
Volume 102, Issue 1 , Pages 12-18 , 1 July 2008

Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome†

  • Almudena Gómez-Hernández, PhD

      Affiliations

    • Vascular Research Laboratory, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • ,
  • Eva Sánchez-Galán, BsC

      Affiliations

    • Vascular Research Laboratory, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • ,
  • Mónica Ortego, PhD

      Affiliations

    • Vascular Research Laboratory, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • ,
  • José Luis Martín-Ventura, PhD

      Affiliations

    • Vascular Research Laboratory, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • ,
  • Luis Miguel Blanco-Colio, PhD

      Affiliations

    • Vascular Research Laboratory, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • ,
  • Nieves Tarín-Vicente, MD

      Affiliations

    • Department of Cardiology, Hospital de Móstoles, Madrid, Spain
    • ,
  • José Julio Jiménez-Nacher, MD

      Affiliations

    • Department of Cardiology, Fundación Hospital de Alcorcón, Madrid, Spain
    • ,
  • Lorenzo López-Bescos, MD

      Affiliations

    • Department of Cardiology, Fundación Hospital de Alcorcón, Madrid, Spain
    • Rey Juan Carlos University, Madrid, Spain.
    • ,
  • Jesús Egido, MD

      Affiliations

    • Vascular Research Laboratory, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • ,
  • José Tuñón, MD

      Affiliations

    • Department of Cardiology, Fundación Jiménez Díaz and Autónoma University, Madrid, Spain
    • Corresponding Author InformationCorresponding author: Tel: 34-91-5504816; fax 34-91-5497033.

Received 18 December 2007 ,Revised 26 February 2008 ,Accepted 26 February 2008.

References 

  1. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  2. Tuñón J, Martín-Ventura JL, Blanco-Colio LM, Egido J. Mechanisms of action of statins in stroke. Expert Opin Ther Targets. 2007;11:273–278
  3. Martín-Ventura JL, Blanco-Colio LM, Muñoz-García B, Gómez-Hernández A, Arribas A, Ortega L, et al. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke. 2004;35:458–463
  4. Gómez-Hernández A, Martín-Ventura JL, Sánchez-Galán E, Vidal C, Ortego M, Blanco-Colio LM, et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis. 2006;187:139–149
  5. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  6. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25:904–914
  7. Wilson SH, Best PJ, Edwards WD, Holmes DR, Carlson PJ, Celermajer DS, et al. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis. 2002;160:147–153
  8. Ritchie ME. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation. 1998;98:1707–1713
  9. Liuzzo G, Santamaria M, Biasucci LM, Narducci M, Colafrancesco V, Porto A, et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol. 2007;49:185–194
  10. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol. 2000;36:1210–1216
  11. Barderas MG, Tuñón J, Dardé VM, De la Cuesta F, Durán MC, Jiménez-Nácher JJ, et al. Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J Proteome Res. 2007;6:876–886
  12. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoids receptors: structures, properties and functions. Physiol Rev. 1999;79:1193–1226
  13. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basic of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921–927
  14. Beloqui O, Paramo JA, Orbe J, Benito A, Colina I, Monasterio A, et al. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur Heart J. 2005;26:153–158
  15. Bäck M, Bu DX, Bränström R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A. 2005;102:17501–17506
  16. Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, et al. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol. 2004;24:1783–1788
  17. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665–1670
  18. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29–37
  19. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, et al Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. JAMA. 2005;293:2245–2256
  20. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233–239
  21. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  22. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  23. Chen F, Eriksson P, Hansson GK, Herzfeld I, Klein M, Hansson LO, et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med. 2005;15:57–65
  24. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions (Association of active enzyme synthesis with unstable angina). Circulation. 1995;91:2125–2131
  25. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, et al Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 2003;107:1479–1485
  26. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke. 2005;36:1796–1800
  27. Xu Z, Zhao S, Zhou H, Ye H, Li J. Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin Chem. 2004;50:750–753

 This study was supported by Grants PI050451, PI052475, and PI051043 from Fundación Española del Corazón, Fondo de Investigaciones Sanitarias; Grant SAF2007/63648 from Fundación Ramón Areces, Madrid, Spain; Sociedad Española de Arteriosclerosis, Barcelona, Spain; Spanish Ministerio de Ciencia y Tecnología; Grant S2006/GEN-0247 from Comunidad Autónoma de Madrid; and Pfizer, Madrid, Spain.

PII: S0002-9149(08)00438-4

doi: 10.1016/j.amjcard.2008.02.090

American Journal of Cardiology
Volume 102, Issue 1 , Pages 12-18 , 1 July 2008

Article Tools

* Image Usage & Resolution